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Abstract
Background: Increased inflammatory cytokines and matrix meta-
lloproteinases (MMPs) have been recently implicated in migraine. In-
flammation may be a key player in the pathophysiology of migraine 
by altering blood-brain barrier (BBB) function. As an inflammation 
induced MMP, MMP-9 is involved in both BBB disruption and neuro-
pathic pain, and is largely derived by neutrophil degranulation during 
neutrophil-BBB interaction. The tetracycline group of antibiotics may 
suppress MMP production and neutrophil degranulation.
Methods/Design: We hypothesize that migraine is a primary neu-
roinflammatory disorder. We will address this theory by measuring 
serum biomarkers in healthy controls and after one of three abortive 
therapy strategies for acute migraine attacks and inter-ictally. We 
intend to investigate known neuroinflammatory biomarkers with a 
focus on BBB breakdown during acute migraine attacks and assess 
marker responses to conventional treatment (triptans), novel MMP 
targeted therapy (doxycycline), or a combination of triptan and do-
xycycline. We will measure the effects of the interventions on neu-
roinflammatory markers for acute migraine attacks, clinical outcomes 
(headache relief and recurrence) for acute migraine attacks, inter-
ictal neuroinflammatory load per serum biomarkers in migraineurs 
versus healthy controls, and neuroinflammatory markers correlation 
with headache duration and peak headache intensity during acute 
migraine attacks.
The impact of triptan and doxycycline on 
neuroinflammatory biomarkers in acute migraine: 
study protocol of a randomized controlled trial
 study Protocol 
1  Neurological Institute, Cleveland Clinic, 
Euclid Ave, S100C, Cleveland OH .
Contact information:
Shaheen E Lakhan, MD, PhD, MEd, MS.
Neurological Institute, Cleveland Clinic, 
9500 Euclid Ave, S100C, Cleveland OH 
44195.
Tel: (216) 444-2200
slakhan@gnif.org
Shaheen E Lakhan, MD, 
PhD, MEd, MS1
InternatIonal archIves of MedIcIne
Section: neurology 
Issn: 1755-7682 
2015
Vol. 8 No. 13
doi: 10.3823/1612
This article is available at: www.intarchmed.com and www.medbrary.com 2
Background
Migraine is a common neurovascular disorder that 
affects over 30 million Americans. There is signi-
ficant economic impact secondary to headache-
related disability [1]. Current theories of migraine 
pathophysiology include cortical spreading depres-
sion (CSD) and neurogenic inflammation [2]. More 
recently, a compromised BBB as a result of neuro-
genic inflammation has been implicated in migraine 
pathophysiology [3].
The BBB protects the brain against compounds 
and pathogens in the blood stream and maintains 
central nervous system homeostatsis. This neuro-
vascular interface is composed of endothelial tight 
junctions, basal lamina, and astrocyte endfeet in the 
brain parenchyma. It is hypothesized that vascular 
inflammation is a common final pathway for migrai-
ne with or without aura [4-8]. A few studies have 
indicated that inflammatory cytokines are elevated 
in migraine patients intra- and inter-ictally [9-13]. 
CSD may create BBB permeability in migraine me-
diated by MMPs and other inflammatory molecules. 
MMPs and tissue inhibitors of MMPs (TIMPs) are 
involved in the remodeling of extracellular matrix via 
chemokines and cellular adhesion molecules. An al-
teration of MMP expression may lead to the break-
down of the BBB, demyelination, cytokine produc-
tion and an inflammatory response, deposition of 
amyloid proteins, and tumor invasion and metas-
tasis [14-18]. In migraine, post-headache levels of 
MMP-9 were significantly higher than controls [19-
22]. MMP-9 potentiates chemokines for leukocyte-
endothelial cell interaction leading to an inflam-
mation cascade at the brain vasculature. The inflam-
mation may be a reason for migraine patients being 
at a higher risk of stroke [8]. Utilizing anti-inflam-
matory and -MMP effect, doxycycline coupled with 
interferon beta-1a reduced multiple sclerosis lesions 
in humans [23] and minocycline prevented hemo-
rrhagic transformation in acute ischemic strokes in 
a rate model treated with IV tPA [24]. However, 
the origin of MMP-9 in migraine patients remains 
unknown, as does the effect of acute migraine 
treatment targeting MMP-9.
Compounds such as triptans and magnesium 
may not cross an intact BBB, however, their utility 
in migraine may be in the setting of BBB disruption. 
Moreover, glucocorticoids, commonly used in acute 
migraine treatment, are known to stabilize the BBB. 
In a migraine animal model, MMP-9 was downre-
gulated with methyl-prednisolone [25]. 
Interestingly, Todd Rozen of the Geisinger Medi-
cal Group has written on doxycycline use as an anti-
inflammatory drug for primary headache disorders, 
especially new daily persistent headache. However, 
he only published one abstract on his open label 
use [26], no peer-reviewed paper, and referred to it 
in a recent review [27].
Discussion: To our knowledge, this trial will be the first systematic 
study on the use of a MMP inhibitor in episodic migraine. Our pilot 
project data will supplement future projects investigating novel the-
rapeutic strategies such as MMP inhibitors in both migraine acute 
treatment and prevention.
Trial Registration: ClinicalTrials.gov NCT01653522, registered 
07/23/2012.
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Methods
Objectives
Primary endpoint:  Determine the effects of oral trip-
tan, doxycycline, and triptan + doxycycline on neu-
roinflammatory markers for acute migraine attacks.
Secondary endpoints:
1.  Compare the effects of oral triptan, doxy-
cycline, and triptan + doxycycline on clinical 
outcomes (headache relief and recurrence) 
for acute migraine attacks.
2.  Determine if inter-ictal neuroinflammatory 
load per serum biomarkers is greater in mi-
graineurs than healthy controls.
3.  Determine if the levels of neuroinflammatory 
markers correlate with headache duration 
and peak headache intensity during acute 
migraine attacks.
Design
This is a single site, randomized, 4 arm open-label 
pilot study of levels of neuroinflammatory markers 
in adult episodic migraineurs and healthy controls 
without migraine. We will recruit participants at a 
major 1,300-bed tertiary teaching hospital, the Cle-
veland Clinic.
We will recruit two groups of patients to partici-
pate in this study: (1) generally healthy adult episo-
dic migraine patients of the Headache Center (the 
“Actives”) or (2) healthy controls who are patients 
(the “Controls”). The “actives” will have migraine 
with or without aura that fulfill the 2nd Edition of 
The International Headache Classification (ICHD-II) 
criteria for episodic migraine. Migraine recruits (“ac-
tives”) will also have an active prescription for an 
oral triptan medication to abort acute migraines. 
The “actives”/migraineurs will not be on a tetracy-
cline group or other anti-inflammatory medication 
for the preceding three months. Informed consent 
will be obtained from all subjects prior to research 
enrollment and subsequent research bloodwork, 
diary use, and medication use.
There will be three treatment arms:
1. Oral triptan (as prescribed)
2. Doxycycline (one dose of 200mg by mouth)
3.  Triptan (as prescribed) + Doxycycline (one 
dose of 200mg by mouth)
There will be one non-treatment arm of “con-
trol” subjects who do not have migraines, will not 
complete a diary, and will have one set of pain free 
bloodwork drawn.
Subjects will be randomly assigned to one of the 
three treatment groups until there are about 10 
subjects in each group. Venous blood during an 
inter-ictal period will be drawn at least seven days 
after the most recent migraine attack. Subjects will 
be telephoned three days after this bloodwork to 
document that they have not experienced a migrai-
ne since the bloodwork was obtained. The subjects 
will be instructed to maintain a headache diary con-
taining the following details: (A) date/time of mi-
graine onset, (B) migraine pain intensity based on a 
four-point scale (0= no pain, 1= mild pain, 2= mo-
derate pain, 3= severe pain); (C) date/time migraine 
treatment medication was taken including medica-
tion name and total dose taken; (D) date/time of 
migraine resolution and (E) date/time of start and 
time of stop for any adverse drug reactions and any 
treatments for those adverse reactions.
The “active” subjects will be instructed to self-
administer oral medication during a migraine attack 
when the pain level is of moderate to severe inten-
sity. Venous blood will be collected at a designed 
lab at a six hour timepoint starting from the time 
migraine treatment is taken. 
Both the “active” subjects and the “controls” 
will also have an inter-ictal (or pain free time for 
the controls) venous blood obtained at a designed 
lab. (The “controls”/healthy volunteers will be sub-
jects without a headache disorder who are age 
and gender matched to the “active” migraineurs 
in the treatment arms.) Both sets of labs will be 
delivered to the processing lab within one hour of 
being drawn, for handling and storage. Specifically 
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the specimens will be centrifuged, pipetted into ali-
quots, labeled, and those sera will be kept at -80˚C 
until further processing is performed. Serum levels 
of MMP-9 (active enzyme), hs-CRP, TNF-alpha, IL-1 
and IL-6 will be measured by ELISA. Once these 
study assays are completed and documented, the 
remaining specimens, if any, will be stored 1 year 
maximally and maybe used for other institutionally 
approved studies related to migraine. After 1 year 
blood samples will be destroyed.
Subject Selection
Sample Size
As this is a pilot study, no formal sample size justifi-
cation is presented. A descriptive statistical analysis 
is provided and seems warranted given the goals 
of the study. 
This study will enroll 40 subjects for participation. 
There are no other sites for this study. 30 subjects 
will be qualified by whether they meet diagnostic 
criteria for episodic migraine with or without aura 
as defined by the ICHD-II and identified as the “ac-
tives”. The remaining 10 subjects will be healthy 
volunteers who do not have migraine diagnosis and 
will be identified as the “controls”.
Additionally the actives will have a current trip-
tan prescription, not be pregnant, and not on a 
medication in the tetracycline group or other anti-
nflammatory medication in the 3 months prior to 
enrollment.
In the event that an enrolled “active” subject 
does not treat a qualifying migraine within 6 weeks 
from enrollment, they will be provided an additio-
nal diary to continue documentation each day of 
any headache activity which they might experience. 
They would be expected to remain in the study until 
they have treated a migraine and had their 6 hour 
blood specimen collected, post-dose. 
Inclusion Criteria
A migraine subject (“active”) will be eligible to par-
ticipate in this study if all of the following criteria 
apply:
1.  subject is 18 years or older at screening
2.  subject has been diagnosed with episodic 
migraine by the ICHD-II criteria
3. subject is not pregnant or nursing
4.  subject has not taken a medication in the te-
tracycline group or anti-inflammatory medi-
cation within the prior 3 months to screening
A healthy subject (“control”) will be eligible to 
participate in this study if all of the following criteria 
apply:
1. subject is 18 year or older at screening
2. subject does not have migraine diagnosis
3. subject is not pregnant or nursing
4.  subject has not taken a medication in the 
tetracycline group or anti-inflammatory me-
dication within the prior 3 months to scree-
ning.
Exclusion Criteria
A subject will not be eligible to participate in this 
study if any of the following criteria apply:
1.  subject is less than 18 years of age at scree-
ning
2.  subject does not have episodic migraine 
diagnosis by the ICHD-II criteria
3.  subject is pregnant or nursing
4.  subject has taken a medication in the tetra-
cycline group or antinflammatory medication 
within the prior 3 months to screening
A randomization schedule will be used to make 
the treatment assignments for the study “active” 
subjects.
     
Study Dosage Regimen
Treatment
Subjects in the “active” arms will be informed of 
their treatment randomization assignment at the 
screening and enrollment visit. The subjects will 
be instructed to self-administer the assigned oral 
medication when the migraine pain is moderate to 
severe in intensity and they are able to return to 
the designed lab at 6 hours after dosing, in order 
to have their blood drawn.
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In the event that an “active” subject experiences 
a migraine on the weekend or at a time when they 
will not be able to return to the Center for Pain to 
have their 6 hour post-dose blood draw obtained, 
they will be instructed to treat that migraine with 
their usual treatment and wait for the next migrai-
ne and use the study drug assignment if that is a 
viable migraine and timepoint. The “active” subjects 
would document all migraines they experience on 
the daily diary. 
Rescue Treatment
Because a primary objective of this study is to obtain 
venous blood specimens at 6 hours post dose, sub-
jects will be asked to not take additional treatments 
prior to having this specimen obtained.
At 6 hours post-dose, if the subject has headache 
pain such that additional treatment is desired, and 
the subject has had the 6 hour post-dose blood 
specimen obtained, the subject will be permitted 
to take a second dose of their assigned treatment 
or in the case of the subject who is assigned to 
doxycycline alone, the subject may treat with the 
usual triptan.
Study Drug Supply
For those subjects who are randomized to the do-
xycycline alone treatment arm or the doxycycline 
and triptan treatment arm, the doxycycline will be 
provided at the screening and enrollment visit.
•   Treatment Assignment will be made according 
to the randomization schedule of the study. 
•   Treatment will be open label.
•   For study product accountability, subjects will 
have documented dispensation of study pro-
duct and will return study drug containers 
when they present for the 6 hour post-dose 
blood draw.
•   Subjects will record treatment use in the study 
diary for the treated migraine attack.
•   Study  drug  supply  will  be  procured,  stored, 
labeled and dispensed to the site.
Study Flowsheet
See Table 1 for the study flowsheet (time and events) 
listing the study activities throughout the protocol.
Table 1:  Study flowchart.
Screen and 
Enrollment 
Visit 
"Actives")
Screen and 
Enrollment 
Visit 
("Controls")
6 Hour 
Post-Dose 
Visit
Procedure 
Informed 
Consent
X X
Inclusion/
Exclusion
X X
Randomization X
Study Drug 
Dispensing
X
Diary 
Instruction and 
Dispensing
X
Urine Pregnancy 
Test
X
Study Drug 
collection
X
Diary Collection X
Phone Call at 3 
Days After Pain 
Free Draw
X X
Pain Free Blood 
Draw
X X
6 Hour Post-
Dose Blood 
Draw
X
Safety
Adverse events will be collected via subject report 
on study diaries and at the blood draw visits. The-
se adverse events will be noted in the electronic 
medical record and will be noted from the date 
of consent signing until the second blood draw is 
completed and the study diary is returned.
Data Analysis
According to the literature (19-22), the 95% confi-
dence interval for the difference in means of MMP-9 
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between the migraine group and the control group 
will be approximately 50 ± 30 ng/mL. It is expected 
that the confidence intervals for the inter-ictal and 
post-treatment differences in the treated group will 
be considerably narrower due to the elimination of 
patient-to-patient variation when analyzing our pri-
mary endpoint. We will also compare clinical outco-
mes in the three treatment arms, but our planning 
statistics will not be powered for this analysis as a 
primary outcome measure.
Individual variables and differences between pre 
and post-treatment will be described with means 
and standard deviation (SD) or medians and inter-
quartile range (IQR). Depending on the distribution, 
parametric or nonparametric confidence intervals 
will be constructed for the difference between 
cases and controls and for the paired differences 
between inter-ictal and post-treatment in the case 
group. JMP 9.0 (SAS Institute) will be used to carry 
out the analyses.
Data Confidentiality
Subject data points will be collected using the data 
from the subject diary and the specimen assays. 
Each enrolled subject will be assigned a study ID 
number which will be used on the diary pages and 
the specimen tubes. A master list identifying each 
subject and their respective ID number will be main-
tained in the study regulatory files. The data analysis 
will all be done with de-identified data. The persons 
with access to the study data would be the study 
investigators and all data will be maintained online 
using the hospital mainframe which is password 
protected.
Ethics and Dissemination
Ethics approval has been obtained from the Insti-
tutional Review Board of the Cleveland Clinic (IRB 
#12-061).
Discussion
We hypothesize that migraine is a primary neuroin-
flammatory disorder. We will address this theory by 
measuring serum biomarkers in healthy controls and 
after one of three abortive therapy strategies for 
acute migraine attacks and inter-ictally. Moreover, 
our pilot project will serve as a foundation for fur-
ther research into neuroinflammatory markers as 
a response to novel therapeutic agents. To our 
knowledge, this would be the first systematic study 
on MMP inhibition for episodic migraine.
Trial Status
Ongoing, entering recruitment-phase.
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BBB: blood-brain barrier; ICHD-II: 2nd Edition of The 
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